About
Loyal is pioneering a new category of preventive veterinary medicine focused on extending the healthy lifespan of dogs. Rather than treating diseases after they emerge, Loyal's approach targets the underlying biological causes of age-associated conditions — helping dogs live longer, healthier lives alongside their owners. Their lead product, LOY-002, is designed for senior dogs aged 10 and older weighing at least 14 lbs. It has completed its Technical Advisory Safety (TAS) package — a critical step toward FDA conditional approval — making it potentially the first FDA-approved longevity drug for dogs. The ongoing pivotal clinical study, STAY, has enrolled over 1,300 senior dogs across 70 veterinary clinics nationwide. LOY-001 and LOY-003 are targeted at large-breed dogs and work by correcting overexpression of IGF-1 and growth hormone (GH) that occurs post-maturity, a known driver of accelerated aging in larger breeds. LOY-001 targets dogs aged 7+ over 40 lbs, while LOY-003 targets dogs aged 5+ over 60 lbs. Loyal works directly with veterinary professionals to integrate these therapies into clinical practice and partners with organizations like Crinetics Pharmaceuticals to accelerate development. The company is backed by a multidisciplinary team of scientists, engineers, and operators united by a mission to give dog owners more time with the pets they love.
Key Features
- LOY-002 Longevity Drug: A lifespan-extending therapy for senior dogs aged 10+ and 14+ lbs that has completed its FDA safety package for conditional approval.
- Large-Breed Metabolic Therapies: LOY-001 and LOY-003 correct overexpression of IGF-1 and growth hormone in large dogs post-maturity, addressing a root cause of accelerated aging.
- STAY Clinical Study: A major pivotal clinical study enrolling 1,300+ senior dogs at 70 veterinary clinics across the U.S. to validate LOY-002's efficacy and safety.
- FDA-Supported Study Design: Loyal's longevity clinical study design is the first of its kind to receive FDA support, setting a regulatory precedent in veterinary medicine.
- Veterinary Professional Integration: Dedicated resources and partnerships for veterinarians to incorporate Loyal's longevity therapies into their clinical practice.
Use Cases
- Senior dog owners seeking preventive care options to extend their dog's healthy years beyond typical life expectancy.
- Veterinarians looking to offer cutting-edge longevity therapies to aging canine patients, especially large breeds prone to early-onset age-related conditions.
- Large-breed dog owners (with dogs 40–60+ lbs) concerned about the accelerated aging associated with elevated IGF-1 and growth hormone levels.
- Veterinary clinics interested in participating in landmark FDA-supported clinical studies for canine longevity drugs.
- Pet health researchers and pharmaceutical professionals tracking regulatory progress in veterinary longevity medicine.
Pros
- Groundbreaking FDA Progress: LOY-002 has cleared critical FDA milestones, positioning it as potentially the first-ever FDA-approved longevity drug for dogs.
- Science-First Approach: Loyal targets the root biological mechanisms of aging rather than treating individual diseases, offering a more comprehensive preventive strategy.
- Large Clinical Evidence Base: With over 1,300 dogs enrolled across 70 clinics, the STAY study generates robust, real-world safety and efficacy data.
Cons
- Products Not Yet Commercially Available: All therapies are still in clinical or pre-approval stages, meaning dog owners cannot yet access them through standard veterinary channels.
- Limited Breed and Age Eligibility: Each product targets specific age and weight ranges, so not all dogs will qualify for every therapy in the pipeline.
Frequently Asked Questions
What is LOY-002 and who is it for?
LOY-002 is Loyal's lead longevity drug designed for senior dogs aged 10 and older weighing at least 14 lbs. It aims to extend healthy lifespan and maintain quality of life as dogs age.
Has Loyal received FDA approval?
Not yet, but LOY-002 has completed its Technical Advisory Safety (TAS) package — a crucial step toward conditional FDA approval. It is also the first dog longevity clinical study design to receive FDA support.
What is the STAY study?
STAY is Loyal's pivotal clinical study for LOY-002, enrolling over 1,300 senior dogs at 70 veterinary clinics across the U.S. to evaluate the drug's ability to extend lifespan and maintain quality of life.
How are LOY-001 and LOY-003 different from LOY-002?
LOY-001 and LOY-003 target large breeds specifically and work by correcting overexpression of IGF-1 and growth hormone post-maturity — a key driver of accelerated aging in bigger dogs. LOY-002 is broader and applies to dogs of nearly all sizes.
How can veterinarians get involved with Loyal?
Veterinary professionals can explore Loyal's dedicated resources on their website, learn about enrolling patients in clinical trials, and stay updated on when therapies will become available for clinical use.
